Last updated: February 19, 2026
This report identifies key suppliers for the active pharmaceutical ingredients (APIs) hydrochlorothiazide and telmisartan. The analysis focuses on manufacturers with significant production capacity, established regulatory compliance, and a presence in major global markets.
Global Hydrochlorothiazide API Suppliers
Hydrochlorothiazide is a widely used thiazide diuretic. Its established market and generic availability necessitate a competitive supplier landscape. Key manufacturers are concentrated in India and China, with some presence in Europe.
Major Hydrochlorothiazide Manufacturers
| Manufacturer Name |
Country of Origin |
Key Certifications |
Annual Production Capacity (Estimated, MT) |
Notes |
| Abbott Laboratories |
United States |
US FDA, EMA, TGA, PMDA |
>500 |
Operates manufacturing facilities globally; significant legacy supplier. |
| Aurobindo Pharma Ltd. |
India |
US FDA, EMA, WHO GMP, COFEPRIS |
>700 |
One of India's largest API exporters; extensive regulatory filings. |
| Dr. Reddy's Laboratories Ltd. |
India |
US FDA, EMA, MHRA, KFDA |
>600 |
Broad API portfolio; strong R&D capabilities and global reach. |
| Teva Pharmaceutical Industries Ltd. |
Israel |
US FDA, EMA, TGA, Health Canada |
>400 |
World's largest generic drug manufacturer; robust supply chain. |
| Sun Pharmaceutical Industries Ltd. |
India |
US FDA, EMA, WHO GMP, ANVISA |
>550 |
Leading Indian pharmaceutical company with a strong API division. |
| Cadila Healthcare Ltd. (Zydus Cadila) |
India |
US FDA, EMA, PMDA, MFDS |
>450 |
Diverse product offerings and a growing global presence. |
| Lupin Limited |
India |
US FDA, EMA, MHRA, KANVISA |
>400 |
Focus on generics and biosimilars; expanding API manufacturing. |
| Shanghai Pharmaceuticals Holding Co., Ltd. |
China |
NMPA, US FDA, EMA |
>300 |
Major Chinese pharmaceutical group with significant API production. |
| Jiangsu Hengrui Medicine Co., Ltd. |
China |
NMPA, US FDA, EMA |
>250 |
Known for R&D and manufacturing of various APIs and finished dosages. |
| Yingzi Pharmaceutical (Group) Co., Ltd. |
China |
NMPA, US FDA, EMA |
>200 |
Significant player in China's pharmaceutical API market. |
| Fresenius Kabi AG |
Germany |
US FDA, EMA |
>150 |
Primarily focused on infusion therapy and generic drugs; has API capabilities. |
Source: Industry intelligence reports, company disclosures, regulatory filings. Production capacities are estimated and subject to change based on market demand and internal strategic adjustments.
Regulatory Landscape for Hydrochlorothiazide
Suppliers must adhere to strict Good Manufacturing Practices (GMP) as mandated by regulatory bodies. Key certifications include:
- US Food and Drug Administration (US FDA): Essential for market access in the United States.
- European Medicines Agency (EMA): Required for the European Union market.
- World Health Organization (WHO GMP): A recognized international standard.
- Therapeutic Goods Administration (TGA) - Australia: For the Australian market.
- Pharmaceuticals and Medical Devices Agency (PMDA) - Japan: For the Japanese market.
- Ministry of Food and Drug Safety (MFDS) - South Korea: For the South Korean market.
- National Medical Products Administration (NMPA) - China: China's primary regulatory authority.
Hydrochlorothiazide Sourcing Considerations
- Pricing Volatility: While hydrochlorothiazide is a mature product, raw material costs and global supply chain disruptions can impact pricing.
- Quality Assurance: Consistent API quality is paramount. Auditing supplier manufacturing sites and reviewing Certificates of Analysis (CoAs) are critical.
- Supply Chain Reliability: Diversifying suppliers can mitigate risks associated with single-source dependency.
- Intellectual Property (IP): For generic manufacturers, ensuring no patent infringement is vital. Hydrochlorothiazide patents have largely expired.
Global Telmisartan API Suppliers
Telmisartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Its market is also characterized by generic competition, though the patent landscape is more complex due to formulation and combination patents.
Major Telmisartan Manufacturers
| Manufacturer Name |
Country of Origin |
Key Certifications |
Annual Production Capacity (Estimated, MT) |
Notes |
| Divi's Laboratories Limited |
India |
US FDA, EMA, WHO GMP, PMDA |
>400 |
A leading global producer of APIs, including telmisartan. |
| Hetero Drugs Limited |
India |
US FDA, EMA, WHO GMP, KFDA |
>350 |
Large-scale API manufacturer with a broad portfolio. |
| Granules India Ltd. |
India |
US FDA, EMA, MHRA, PMDA |
>300 |
Vertically integrated operations from key starting materials to APIs. |
| Natco Pharma Limited |
India |
US FDA, EMA, PMDA, MFDS |
>250 |
Focus on niche generics and complex APIs. |
| Mylan N.V. (now Viatris) |
United States |
US FDA, EMA, TGA, Health Canada |
>200 |
Extensive generic drug development and manufacturing capabilities. |
| Cipla Limited |
India |
US FDA, EMA, WHO GMP |
>200 |
Long-standing pharmaceutical company with a robust API division. |
| Zhejiang Huahai Pharmaceutical Co., Ltd. |
China |
US FDA, EMA, NMPA |
>300 |
Significant global supplier of ARBs and other cardiovascular APIs. |
| Sichuan Kelun Pharmaceutical Co., Ltd. |
China |
NMPA, US FDA, EMA |
>250 |
A major Chinese pharmaceutical enterprise with substantial API capacity. |
| Piramal Enterprises Limited |
India |
US FDA, EMA |
>150 |
Contract development and manufacturing organization (CDMO) with API capabilities. |
| Jubilant Life Sciences Limited |
India |
US FDA, EMA, WHO GMP |
>150 |
Offers a range of APIs and pharmaceutical services. |
Source: Industry intelligence reports, company disclosures, regulatory filings. Production capacities are estimated and subject to change.
Regulatory Landscape for Telmisartan
Similar to hydrochlorothiazide, telmisartan API suppliers must meet stringent regulatory requirements. The same key certifications (US FDA, EMA, WHO GMP, etc.) are critical.
Telmisartan Sourcing Considerations
- Combination Product Patents: Telmisartan is frequently formulated with other antihypertensives (e.g., hydrochlorothiazide, amlodipine). Patent protection for these combination products can extend beyond the telmisartan API patent. Manufacturers must be aware of the IP landscape for specific finished dosage forms.
- Impurity Profiles: Regulatory agencies scrutinize impurity profiles. Suppliers must demonstrate control over critical impurities, particularly nitrosamines, which have been a focus for ARBs.
- Supply Chain Security: Ensuring a stable and secure supply chain is essential, especially for a drug used in chronic treatment regimens.
- Cost-Effectiveness: While quality is paramount, competitive pricing from multiple qualified suppliers is a key factor for generic drug manufacturers.
Key Takeaways
- Dominant Suppliers: India and China are the primary global hubs for the manufacturing of both hydrochlorothiazide and telmisartan APIs.
- Regulatory Compliance is Non-Negotiable: US FDA and EMA certifications are standard requirements for market access in major Western economies. Manufacturers must demonstrate robust quality management systems.
- Strategic Sourcing: Pharmaceutical companies should maintain relationships with multiple qualified suppliers to ensure supply chain resilience and competitive pricing.
- Intellectual Property Awareness: For telmisartan, understanding the patent landscape for both the API and potential combination products is crucial.
- Impurity Control: Suppliers must have rigorous processes for controlling critical impurities, a focus area for global regulatory bodies.
Frequently Asked Questions
1. What are the primary geographical regions for API manufacturing of hydrochlorothiazide and telmisartan?
The primary manufacturing regions are India and China, which host the largest number of API producers with significant production capacities and established regulatory approvals.
2. Which regulatory bodies are most critical for API suppliers to be accredited by?
The US Food and Drug Administration (US FDA) and the European Medicines Agency (EMA) are critical for market access in the United States and the European Union, respectively. Other significant bodies include the World Health Organization (WHO GMP), Japan's PMDA, and various national regulatory authorities.
3. Are there significant patent concerns for generic hydrochlorothiazide and telmisartan APIs?
For hydrochlorothiazide, most relevant patents have expired, leading to a highly competitive generic API market. Telmisartan's API patent has also expired in many regions, but patents for specific formulations, combination products, and manufacturing processes may still exist and require careful evaluation by generic manufacturers.
4. What are the key factors to consider when selecting an API supplier for these drugs?
Key factors include the supplier's regulatory compliance (US FDA, EMA approvals), manufacturing capacity and reliability, quality control processes, impurity profiles, pricing, and the overall stability of their supply chain.
5. How has the focus on nitrosamine impurities affected telmisartan API suppliers?
The presence of nitrosamine impurities has led to increased scrutiny of ARB APIs, including telmisartan. Suppliers must demonstrate rigorous control over their manufacturing processes to prevent the formation of these impurities and provide validated analytical methods for their detection.
